They are not doing a formal efficacy analysis, but just safety analysis. Of course DMSC will know how many people have died in each arm and if any deaths is linked to the drug(s).
So I do not expect any formal communicatioin regarding efficacy.
My only doubt is: what heppens if DMSC sees that in the VBL111 arm there are for instance double survivors compared to the Avastin arm, ie that there is such overwhelming evidence of efficacy that no fine analysis is really needed? Can they , with the FDA blessing, recommend a trial halt anyway?
News 
Market Data 
Discover 
